Stephen V Liu, MD

Registration open for #DCLung26 on 10/10/26 - with 77 expert multi-disciplinary faculty from the US & abroad, this will be our biggest yet. High yield talks with engaging panel discussions on how to implement new standards of care and best practice! medstarhealth.org/dclung

What happens to pts with resectable NSCLC who don’t make it to surgery after neoadjuvant chemo-immunotherapy?@JTOonline In this multicenter study (n=57), definitive RT is a valid alternative: 👉 1-year OS 81% 👉 mPFS 16.1 mo 👉 Pneumonitis 18% 🔬 pubmed.ncbi.nlm.nih.gov/41852936/

🃏Shuffle up & deal! The Dealer himself, Dr. @JSabari, will be in the pit for the Texas Lung Hold 'Em debate at #TexasLung26! Surgical vs Non-surgical Approaches to Early-Stage Lung Cancer —high stakes, no folding allowed! Will the chips fall for blades or beams? Dr. Sabari's dealing the evidence straight. April 9-11, Austin TX | FREE registration with code FREECME →na2.hubs.ly/H04nFHn0 #LungCancer #ThoracicOncology

🫁 Catching up on news from #BTOG26 ahead of #ELCC26? ⭐ Don't miss this insightful new interview with @marialuciareale, who joined us to share key highlights from BTOG 2026! ➡️ Watch now: buff.ly/IJ2oC6j #NSCLC #lcsm #LungCancer

On the next episode of the @IASLC podcast, Lung Cancer Considered, I sit down with members of the Global Policy and Partnerships Committee to learn how policy impacts lung cancer research, treatment, and prevention. Thanks to Drs. @AndreasC466 @SamuelKareffMD @nicole_rankin8n!

More disappointment with anti-TIGIT therapy. Results from phase III KEYVIBE-010 study of adjuvant vibostolimab coformulated with pembrolizumab versus pembro alone in resected melanoma fails to improve recurrence free survival (HR 1.25) and adds toxicity. thelancet.com/journals/lanon…

ALL IN at #TexasLung26! 🃏 The first-ever Texas Lung Hold 'Em debate "Surgical vs Non-surgical Approaches to Early-Stage Lung Cancer" is coming to ACL Live and the stakes couldn't be higher! Dealing the cards: Dr. @JSabari Perioperative Therapy and Surgery: Dr. @BrendonStilesMD Definitive Chemoradiation and Consolidation: Dr. @SalmaJabbour1 Pit bosses Drs. @StephenVLiu & Tina Cascone watching the action! Who's got the winning hand? Join us on April 9-11 in Austin, TX to find out. → na2.hubs.ly/H04lqsy0 #LungCancer #ThoracicOncology

Longer follow up from LUMINOSITY study @JTOonline: telisotuzumab vedotin (cMET ADC) in cMET+, EGFR wild type, non-squamous NSCLC had RR 29.2% with DOR 7.2m. In cMET high, RR 34.5% and in cMET int, RR 23.8%. Neuropathy seen in 31% (7% G3+). jtocrr.org/article/S2666-…

Enjoyed discussing our different approaches to the same challenges at the 2026 Summit at the Summit. It's enormously helpful to understand different perspectives and come together to prioritize future directions. Thanks to chairs @PatelOncology @benlevylungdoc @christine_lovly

Oncology Fellows: Get your research to Chicago! Join us for the 4th Annual National Fellows Forum: Lung Cancer (May 28). We’re selecting 75 fellows for an all-expenses-paid trip! Apply: hubs.li/Q046Wxdj0 @benlevylungdoc @hopkinskimmel @StephenVLiu @Georgetown @MedStarGUH @LombardiCancer @drshieldsmd @TheShieldsLab @SclcSMASHERS @IndianaUniv @christine_lovly @CityofHope

🗨️ What are the key debates in thoracic cancer? ⭐ Don't miss this interview with @StephenVLiu, who joined us to share insights and highlights from the International Thoracic Cancer Debates. ➡️ Watch: buff.ly/TfsVYN3 #ITCD26 #lcsm #NSCLC #SCLC #LungCancer

When @ShooterMcGavin tells you to pay attention… you pay attention! At the 4th annual #TexasLung26, all the chips will be on the table for the first-ever Texas Lung Hold ’Em debate! Surgical vs Non‑Surgical Approaches to Early‑Stage Lung Cancer 👥 Drs. @BrendonStilesMD vs @SalmaJabbour1 🂡 Dealer: Dr. @JSabari Pit Bosses: Drs. @StephenVLiu and Tina Cascone utm.rocks/umvaf Join us! Austin, TX | April 9–11, 2026 | Registration is FREE with code FREECME

Results from CHIO3 (CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer), AFT-46 study online. Phase II study of durvalumab + neoadjuvant chemo showed N2 nodal clearance rate of 73%, pCR 30%. lungcancerjournal.info/article/S0169-…

Congratulations to @benweinbergmd on receiving the John F. Potter, M.D. award during last night's @LombardiCancer Gala. This award recognizes the achievements of rising-star researchers who are moving the needle of progress forward through innovation and persistence.

So helpful to hear everyone’s perspectives on the current state of lung cancer care and the most promising future directions at the Summit at the Summit in Utah! @benlevylungdoc @marinagarassino @PatelOncology @riess_md @LudaBazhenovaMD @wakelee

Multidisciplinary care is the future of lung cancer education Amazing program led by @caliraf @Piuchagarrido and Fiona Blackhall for the @myESMO Lung Cancer Preceptorship in Manchester with 100+ colleagues committed to improving patient care. #LungCancer #ThoracicOncology #ESMO #lcrf @OncoAlert

Ready for some spirted discussion on the current best approaches to treating lung cancer at the “Summit at the Summit” in Utah with @benlevylungdoc and @PatelOncology.

Phase I ARTEMIS-001 trial of the B7-H3 ADC HS-20093 (GSK5764227) now @Cancer_Cell. In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%), but no difference by platinum sensitivity. B7-H3 IHC not predictive. cell.com/cancer-cell/fu…

SEMIFINALS BOUND 😤 #HoyaSaxa #HoyaBold

Phase III CAMPASS study @TheLancetOncol: first line benmelstobart (PD-L1) plus anlotinib vs pembrolizumab in PD-L1 positive NSCLC. Benmelstobart + anlotinib superior PFS (11 vs 7.1m, HR 0.70) but higher AEs (most common G3+ was HTN at 26%). OS immature. thelancet.com/journals/lanon…

Unlock the latest in targeted approaches for early-stage and locally advanced lung cancer. Led by chair Dr. Jonathan Goldman and panelists Drs. @NarjustFlorezMD, @DrRoyHerbstYale, @DrewMoghanaki, Don Gibbons, @KMilehamMD, @RamalingamMD, and @BorisSepesi. This is the can't-miss deep dive you need! Come join us at #TexasLung26, April 9–11, 2026 at @acllive in Austin. FREE REGISTRATION with code FREECME today! → na2.hubs.ly/H04fLQS0 #NSCLC #TargetedTherapy #ThoracicOncology